Insulin-like growth factor binding protein (IGFBP)-2 has mitogenic effects in normal and neoplastic cells. The purpose of this study is to examine the diagnostic and prognostic significance of elevated IGFBP-2 levels in children with AML after hematopoietic stem cell transplantation (HSCT) at relapse and continuous complete remission (CCR). In 27 children with AML (mean age 13.675.3 years; patients in remission n ¼ 15 with relapse n ¼ 12) serum parameters of IGFBP-2, IGFBP-3, IGF-I and IGF-II were analyzed up to 18 months after HSCT by RIA. AML-patients with evidence of relapse demonstrated a continuous increase of IGFBP-2 levels during the follow-up. At day 100 after HSCT, IGFBP-2 concentrations were significantly higher in patients with relapse than in children without relapse (7.474.0 standard deviation score (SDS) vs 3.971.7 SDS; P ¼ 0.01). Serum IGFBP-2 was identified as an independent factor for the prediction of relapse. Furthermore, the probability of relapse-free survival (RFS) in patients with IGFBP-2 44.5 SDS at day 100 after HSCT was 31% compared to patients with IGFBP-2 o4.5 SDS was 72% (P ¼ 0.004). Patients with IGFBP-2 concentration up to 4.5 SDS more likely developed a relapse and had a poorer outcome. Identification of these patients allows a more individualized and aggressive adjuvant treatment and follow-up.
Introduction
The use of intensive chemotherapy has produced improvements in the outcome for pediatric patients with acute myeloid leukemia (AML). This has been demonstrated in studies by the major cooperative groups. 1 Nonetheless, despite high-intensity chemotherapy and bone marrow transplantation, only about half of the children diagnosed with AML are cured. 2, 3 Future improvements are unlikely to come from further increases in chemotherapy intensity. 1, 4 Alternative approaches, such as risk-directed therapy based on different prognostic criteria, may lead to further advances. 5, 6 In point of fact, more reliable markers and potential therapeutic targets are required to assist with prognosis and earlier relapse. Insulin-like growth factor systems (IGF-systems) stimulate cellular proliferation and differentiation of normal and transformed cells. 7, 8 Insulinlike growth factors (IGFs)-I and -II are structurally related polypeptides, which play an important role in cellular proliferation, differentiation and apoptosis. 9, 10 They are regulated by a family of binding proteins (IGFBPs), of which six have been identified. 11 The IGFBPs modulate the biological action of IGF-I and IGF-II. 12 In addition, some IGFBPs have been found to have direct effects on cellular growth and apoptosis independent of IGFs. IGFBPs have been found in association with several malignant tumors. 13, 14 It has been demonstrated that normal lymphocytes and lymphoblast cell lines express and secrete IGFs and IGFBPs. 15 Our previous study demonstrated significantly increased IGFBP-2 levels in serum of leukemia patients compared to healthy subjects. 16 Little is known about changes of the IGF-system in children with myeloid leukemia after HSCT. This study aimed to investigate components of the IGF system for their predictive value in identifying patients with an increased risk of relapse after HSCT.
Patients and methods

Patient population
We investigated 27 patients (mean age 13.675.3 years; 11 female, 16 male) suffering from AML who were first treated with either a bone marrow transplantation (n ¼ 17) or with a stem cell transplantation (n ¼ 10) at a single center. The characteristics of the 27 patients and conditioning regimens are summarized in Table 1 . Thirteen patients received autologous HSCT and 14 patients underwent allogeneic HSCT. Nine out of the 13 patients with autologous transplantation received bone marrow. The other four patients received stem cells. The median cell dose in these patients was 3.5 Â 10 8 cells/kg (3.5 Â 10 6 cells/kg CD34 þ cells and 7.0 Â 10 6 cells/kg CD3 cells). The 14 patients with allogeneic transplantation (11 with bone marrow, three with stem cells) received in median 3.2 Â 10 8 cells/kg (9.0 Â 10 6 cells/kg CD34 þ cells and 23.5 Â 10 6 cells/kg CD3 cells). Out of these allogeneic transplantations, 11 were matched related donors, two were matched unrelated donors and one was a haploidentical related donor. Erythrocyte depletion was necessary in four grafts because of a major incompatibility situation. None of the included patients received grafts that were T-cell depleted or CD34 þ selected. Twelve out of 14 patients with an allogeneic transplantation developed an acute GvHD; whereas five developed a chronic GvHD. Seven out of 12 patients with relapse during the follow-up developed a GvHD as well (Table 2) .
Study design and laboratory investigations
Patients were investigated 7 days prior to, and 30, 60 and 100 days as well as 6, 12, and 18 months after HSCT and at relapse. All patients were in complete remission confirmed by bone marrow aspiration and morphological diagnostics before transplantation.
Fourteen patients were available for follow-up at 12 and 18 months. Leukemic relapse occurred in 12 patients at a median of 8.5 month after BMT ( Figure 1 ).
All used serum samples were residues from routine laboratory measurements. Blood samples for determination of the IGF-parameters and binding proteins were frozen at À701C until measurement.
Serum measurements
IGF-I,-II and IGFBP-2, 3 were investigated by specific RIAs as described previously in detail. 17 IGFBP-2 serum concentrations were measured by an established competitive RIA using a polyclonal rabbit antiserum raised against recombinant human IGFBP-2 (DSL, Webster, TX, USA). 18 Diluted samples were incubated with polyclonal anti-IGFBP-2 antibody and 125 I-IGFBP-2 for 20 h at 41C. Separation of the bound fraction was accomplished by the addition of a second antibody and polyethylene glycol. The lower limit of detection was 0.5 ng/ml. The Intra-assay coefficient of variation was 5.7% and the inter-assay coefficient of variation was 6.3%.
IGF-I analyses were performed by RIA after acidethanol extraction (RIA; Biochem immumosystems, Freiburg, Germany). 19 The sensitivity limit of this assay was 12 ng/ml. The Intra-and inter-assay coefficient of variation were 3.8 and 5.1%, respectively.
IGF-II and IGFBP-3 were analyzed by immunoradiometric assay (IRMA; DSL, Webster, TX, USA). 20 The sensitivity limits of these assays were lower than 40 ng/ml for IGF-II and 0.5 ng/ml for IGFBP-3, respectively. The absolute values of all four parameters were converted standard deviation score (SDS) adjusting for age and sex. This conversion was necessary because of the age-and sexdependence of the normal ranges during childhood. Samples were processed in multiple assays to confirm that measurements remained constant for each of the peptides. Cox regression was used to test whether or not different factors influenced the relapse-free survival (RFS) of patients. A cutoff point was determined only for these factors, where a significant increased risk of relapse could be found. To define the cutoff point of IGFBP-2, sensitivity and specificity were calculated as ROC curves. The optimum was defined as the point where the sum of the specificity and sensitivity was maximal and was confirmed by Cox regression with relative risk as the criterion. With this procedure the cutoff point for IGFBP-2 was selected. RFS was defined as the time from HSCT until the date of the first relapse. The probability of RFS, according to IGFBP-2 at day 100 after HSCT, was estimated by the Kaplan-Maier curve and was compared with the log-rank test. Missing data were inferred by calculating the mean values of all patients. All investigations were strictly performed in accordance with the guidelines of the local ethics committee.
Results
In accordance with our previous report on patients with acute leukemia, serum concentrations of circulating IGF-I, IGF-II, IGFBP-2 and IGFBP-3 changed significantly after transplantation. 16 The levels of circulating IGFBP-2 in patients with AML showed a continuous increase up to 100 days after HSCT and at the same time a decrease of IGF-I and IGFBP-3 ( Figure 1, Table 3 ). No change was observed for IGF-II. The normal range is given between 72 SDS.
In contrast, serum levels were significantly different between patients in CCR and patients with a relapse after HSCT. Patients with relapse showed remarkable higher IGFBP-2 levels than patients in CCR. Serum IGFBP-2 in patients with relapse was elevated to more than þ 2 SDS prior to HSCT (mean7s.d.: 4.673.4 SDS; Figure 1) . Furthermore, patients with evidence of relapse demonstrated a continuous increase of IGFBP-2 levels. IGFBP-2 concentration was significantly higher in patients with relapse than in children without relapse at day 100 after HSCT (7.474.0 SDS vs 3.971.7 SDS; P ¼ 0.01; Table 3 ). By means of the Cox regression analysis, IGFBP-2 could be rated as an independent parameter on day 100 after transplantation (P ¼ 0.004).
Furthermore, serum levels of IGFBP-2 were identified as an independent factor for the prediction of relapse at 100 days after transplantation (Cox regression, P ¼ 0.004, Table 3 ). The cutoff point was analyzed by calculating for different values and displayed as ROC curves (P ¼ 0.004, Figure 2) . The optimum was defined as the point where the sum of specificity and sensitivity was maximal, and was confirmed by Cox regression with relative risk as the criterion. With this procedure, a cutoff point of þ 4.5 SDS for IGFBP-2 was selected. The relapsefree survival probability at 10 years was 52% for all patients with AML after HSCT. The Kaplan-Meier plots demonstrated that RFS in patients with increased IGFBP-2 levels higher than 4.5 SDS at day 100 after HCST, is associated with a poorer outcome. The probability for RFS after HSCT in patients with IGFBP-2 levels higher than 4.5 SDS at day 100, was 31% as compared to 71.4% in patients with IGFBP-2 levels lower than 4.5 SDS (P ¼ 0.004; Figure 2 ). Table 3 Insulin like growth factor-I,-II and IGF-binding protein-2,-3 levels at day 100 after HSCT in patients with CCR and patients with evidence of relapse Figure 2 A 5-year probability of relapse-free survival (RFS) after HSCT in relation to serum IGFBP-2 concentration at day 100 after transplantation. Patients were divided into two groups according to their serum concentration at day 100 after HSCT. Patients with IGFBP-2 levels o4.5 SDS (N ¼ 14; 3 events; RFS 72%, C.I. 6.9-13.1) had a significantly better outcome (P ¼ 0.004) than patients with IGFBP-2 levels 44.5 SDS (N ¼ 13; 9 events; RFS 31%, C.I. 1.6-7.4).
The kind of transplantation (allogeneic or autologous) as well as acute and chronic GvHD after transplantation did not demonstrate a significant influence on the investigated IGF or IGFBP levels. In contrast, serum IGF-I and IGFBP-3 demonstrated a continuous decrease up to 100 days after HSCT. IGF-I and IGFBP-3 in patients with CCR normalized 18 months after transplantation. Comparing patients with relapse after HSCT and patients in CCR, a significant decrease was observed for serum concentration of IGFBP-3 at day 100 after transplantation, and a trend was observed for IGF-I. The Cox regression analysis of IGFBP-3 and IGF-I demonstrated only a trend ( Table 3) .
Discussion
Intensive myelosuppressive therapy is necessary to improve the outcome for patients with acute myeloid leukemia. HSCT represents the most intensive therapy in the treatment of leukemia. It offers the opportunity for a better survival prediction for high-risk patients. 21 It is well accepted that the leukemic relapse after HSCT is associated with the disease level prior to transplantation as well as the minimal residual disease status after transplantation. 22, 23 New reports suggest a correlation between an increased number of minimal residual leukemic cells in bone marrow and the probability of relapse. 24 Actually, more reliable markers and potential therapeutic targets are required to assist with prognosis and earlier relapse.
Insulin-like growth factors and the specific-binding proteins, especially IGFBP-2, showed a high association with stimulated cellular proliferation and differentiation in normal and malignant cells.
High serum IGFBP-2 levels might be directly correlated to a higher rate of malignant cellular growth. 25 An overexpression of IGFBP-2 in adrenocortical tumor cells resulted in increased malignant growth and changed cellular morphology. 26 Furthermore, it is known that increased IGFBP-2 serum concentration at diagnosis in children with acute leukemia serves as a negative prognostic factor. 27 The presented study investigated IGF and IGFBPs. Its goal aimed to investigate if components of the IGF system can be used to improve the prediction of survival and to identify risk factors for a relapse prediction after hematopoietic stem cell transplantation. Significant higher IGFBP-2 levels and decreased IGFBP-3 levels at day 100 after transplantation were seen in patients with relapse as compared to those in CCR. Alterations in the IGF system with the same constellation, with high IGFBP-2 levels and low IGFBP-3 levels, have also been described in many cell types including hematopoietic cells, carcinomas and neuroblastomas. [27] [28] [29] [30] To the best of our knowledge, this is the first study investigating IGF parameters as possible prediction factors for survival during long-term follow-up after transplantation.
Both patients in CCR and patients with relapse demonstrated a continuous increase of IGFBP-2 within the first weeks after transplantation. An increase of IGFBP-2 expression might be directly correlated to the increased cell proliferation rate. 31 Hettmer et al. 32 recently published data demonstrating that incubation with exogenous IGFBP-2 increased the proliferation of PBMC; whereas, anti-IGFBP-2 had an antiproliferative effect on PBMC that was reversed by simultaneous exposure to IGFBP-2. These data strongly suggest a role for IGFBP-2 as a local growth factor contributing to the proliferation and activation of mononuclear cells. 32 The continuous increase of IGFBP-2 levels in the first weeks after transplantation are associated with the proliferation and differentiation of the graft cells and may be involved in the bone marrow recovery. The disease recurrence after transplantation is associated with a high proliferation rate of leukemic cells, expecting higher IGFBP-2 levels in patients developing a relapse. On the other hand, clinical studies have demonstrated that the occasionally high IGFBP-2 levels in leukemic serum normalize after hematological remission following chemotherapy. 29 The same phenomena could be found during follow-up in our study for patients with CCR.
The results of our study demonstrated a significant difference between patients in CCR and evidence of relapse at day 100 after transplantation. Patients with higher IGFBP-2 levels at day 100 after HSCT were more likely to relapse; those with levels 44.5 SDS had a significantly worse overall survival. Similar evidence was confirmed by Vorwerk et al., 33 who demonstrated that components of the IGF system are linked to the outcome of childhood ALL. In vitro experiments recently found evidence that leukemic T cells could cause elevated IGFBP-2 concentrations in leukemic serum. 34 It could be postulated that IGFBP-2 has a direct stimulating and proliferating effect on leukemic cells. However, the actual mechanism of IGFBP-2 action remains unclear. 35 The assumed proliferative effect within the last years of the IGF-systems was conducted on an IGF-dependent action. New publications also suggest an IGF-independent action. Early investigations of IGFindependent actions of IGFBPs have implicated a large array of signaling proteins with links to cell cycle control and apoptosis. 35 Furthermore, there are cues for an integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. 36 These data demonstrate that IGFBP-2 can act in an IGF-independent manner, as well. 35 Whether or not IGFBP-2 alone or in combination with IGFBP-3 and IGF-I promote the mitogenic effect on leukemic cells is still a matter of discussion. An interaction with the IGF-I-receptor is also possible. 37 Furthermore, the different conditioning regimens and the occurrence of graftversus-host disease had no influence on changes in serum IGFs and IGFBPs in our patients. These findings are supported by the results of Munker et al. 38 They found no direct correlation between both the IGF-system and the severity of graft-versus-host disease as well as levels of interleukin-6 and the time to hematopoietic recovery.
The results of our study demonstrated significant differences between patients in CCR and patients with evidence of relapse at day 100 after transplantation. Patients with higher IGFBP-2 at day 100 after HSCT were more likely to relapse. The IGFBP-2 levels 44.5 SDS were associated with a worse overall survival. Identification of these patients at day 100 allows a more individualized, aggressive adjuvant treatment and follow-up. IGFBP-2 may be an important additional prognostic marker in this disease. In summary, the findings of this study support the role of IGFBP-2 as a possible prognostic marker in children with AML after HSCT. Additional patients are being accrued to the study; whereas those already enrolled continue to be followed. Additional investigations are being performed to determine how IGFBP-2 may regulate myeloid leukemic cells after transplantation.
